DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors
MINNEAPOLIS--(BUSINESS WIRE)--Jul 15, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Companyâs Board of Directors. Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical industry. Dr. Charles Semba, Chief Medical Officer of Eluminex Biosciences, has over 20 years of drug-deve...
Source: cadillacnews.com